Safinamide inhibition of in vivo glutamate release in a rat model of Parkinson's Disease

被引：0
|
作者：
Padoani, G.
Novello, S.
Pisano, C.
Caccia, C.
Melloni, E.
Vailati, S.
Keywood, C.
Morari, M.
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
182
引用
收藏
页码：S81 / S82
页数：2
相关论文
共 50 条
  • [31] SURINPARK: Safinamide for urinary symptoms in Parkinson's disease
    Gomez, A.
    Beltran Corbellini, A.
    Natera Villalba, E.
    Sanchez Sanchez, A.
    Perez Torre, P.
    Fanjul Arbos, S.
    Lopez Sendon-Moreno, J. L.
    Martinez Castrillo, J. C.
    Parees, I.
    Alonso Canovas, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 470 - 470
  • [32] PET studies: in vivo monitoring of group I metabotropic glutamate receptors in Parkinson's disease rat
    Yamasaki, T.
    Fujinaga, M.
    Kawamura, K.
    Shimoda, Y.
    Furutsuka, K.
    Nengaki, N.
    Yui, J.
    Wakizaka, H.
    Hatori, A.
    Xie, L.
    Kumata, K.
    Zhang, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S623 - S624
  • [33] Evaluation of the effectiveness of safinamide in a Spanish population with Parkinson's disease
    Freire-Alvarez, E.
    Esquivel, A.
    Gomez-Esteban, J.
    Kulisevsky-Bojarski, J.
    Legarda-Ramirez, I.
    Alvarez-Santullo, M. Mata
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 515 - 515
  • [34] Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
    Stocchi, Fabrizio
    Torti, Margherita
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 609 - 618
  • [35] Clinical pharmacology review of safinamide for the treatment of Parkinson's disease
    Fabbri, Margherita
    Rosa, Mario M.
    Abreu, Daisy
    Ferreira, Joaquim J.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2015, 5 (06) : 481 - 496
  • [36] The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review
    Sharaf, Joudi
    Williams, Kerry-Ann D.
    Tariq, Maha
    Acharekar, Maitri, V
    Saldivia, Sara E. Guerrero
    Unnikrishnan, Sumedha
    Chavarria, Yeny Y.
    Akindele, Adebisi O.
    Jalkh, Ana P.
    Eastmond, Aziza K.
    Shetty, Chaitra
    Rizvi, Syed Muhammad Hannan A.
    Mohammed, Lubna
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [37] Assessment of the effects of safinamide on the clinical treatment of Parkinson's disease
    Guan, Zaifeng
    Gu, Jingjing
    Hu, Guifang
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 : 292 - 292
  • [38] Safinamide: an add-on treatment for managing Parkinson's disease
    Mueller, Thomas
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2018, 10 : 31 - 41
  • [39] The Proteasome Inhibition Model of Parkinson's Disease
    Bentea, Eduard
    Verbruggen, Lise
    Massie, Ann
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 (01) : 31 - 63
  • [40] Glutamate and Parkinson's disease
    Blandini, F
    Porter, RHP
    Greenamyre, JT
    MOLECULAR NEUROBIOLOGY, 1996, 12 (01) : 73 - 94
12345